Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
Bot Image has developed ProstatID, aiding in the early diagnosis of prostate cance...
Bot Image has developed ProstatID, aiding in th...
Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company committing...
Pieris Pharmaceuticals, Inc. is a, clinical-sta...
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device compan...
Cardiovascular Systems, Inc., based in St. Paul...
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers...
Gilead Sciences, Inc. is a research-based bioph...
We are a clinical-stage biopharmaceutical company focused on improving the lives o...
We are a clinical-stage biopharmaceutical compa...
At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients w...
At ACADIA (NASDAQ: ACAD), we share a passion fo...
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering,...
Gossamer Bio is a clinical-stage biopharmaceuti...
Join the National Investor Network and get the latest information with your interests in mind.